Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012
- PMID: 24833561
- DOI: 10.1016/j.radonc.2014.03.024
Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012
Abstract
Background and purpose: In 2003 we estimated that 52.3% of new cases of cancer in Australia had an indication for external beam radiotherapy at least once at some time during the course of their illness. This update reviews the contemporary evidence to define the optimal proportion of new cancers that would benefit from radiotherapy as part of their treatment and estimates the changes to the optimal radiotherapy utilisation rate from 2003 to 2012.
Materials and methods: National and international guidelines were reviewed for external beam radiotherapy indications in the management of cancers. Epidemiological data on the proportion of new cases of cancer with each indication for radiotherapy were identified. Indications and epidemiological data were merged to develop an optimal radiotherapy utilisation tree. Univariate and Monte Carlo simulations were used in sensitivity analysis.
Results: The overall optimal radiotherapy utilisation rate (external beam radiotherapy) for all registered cancers in Australia changed from 52.3% in 2003 to 48.3% in 2012. Overall 8.9% of all cancer patients in Australia have at least one indication for concurrent chemo-radiotherapy during the course of their illness.
Conclusions: The reduction in the radiotherapy utilisation rate was due to changes in epidemiological data, changes to radiotherapy indications and refinements of the model structure.
Keywords: Evidence-based practice; Radiotherapy; Standards; Utilisation.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Estimation of an optimal chemotherapy utilisation rate for cancer: setting an evidence-based benchmark for quality cancer care.Clin Oncol (R Coll Radiol). 2015 Feb;27(2):77-82. doi: 10.1016/j.clon.2014.10.004. Epub 2014 Oct 31. Clin Oncol (R Coll Radiol). 2015. PMID: 25455844 Review.
-
Estimation of an optimal utilisation rate for palliative radiotherapy in newly diagnosed cancer patients.Clin Oncol (R Coll Radiol). 2010 Feb;22(1):56-64. doi: 10.1016/j.clon.2009.11.003. Epub 2009 Dec 6. Clin Oncol (R Coll Radiol). 2010. PMID: 19969443
-
Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines.Cancer. 2006 Jan 15;106(2):453-65. doi: 10.1002/cncr.21596. Cancer. 2006. PMID: 16355366
-
Estimation of the optimal utilisation rates of radical prostatectomy, external beam radiotherapy and brachytherapy in the treatment of prostate cancer by a review of clinical practice guidelines.Radiother Oncol. 2016 Jan;118(1):118-21. doi: 10.1016/j.radonc.2015.12.023. Epub 2016 Jan 8. Radiother Oncol. 2016. PMID: 26776443
-
Evidence-based estimates of the demand for radiotherapy.Clin Oncol (R Coll Radiol). 2015 Feb;27(2):70-6. doi: 10.1016/j.clon.2014.10.005. Epub 2014 Nov 1. Clin Oncol (R Coll Radiol). 2015. PMID: 25455408 Review.
Cited by
-
Ferrite Nanoparticles-Based Reactive Oxygen Species-Mediated Cancer Therapy.Front Chem. 2021 Apr 27;9:651053. doi: 10.3389/fchem.2021.651053. eCollection 2021. Front Chem. 2021. PMID: 33987168 Free PMC article. Review.
-
The linker of nucleoskeleton and cytoskeleton complex is required for X-ray-induced epithelial-mesenchymal transition.J Radiat Res. 2023 Mar 23;64(2):358-368. doi: 10.1093/jrr/rrac104. J Radiat Res. 2023. PMID: 36694940 Free PMC article.
-
The Rational Design and Biological Mechanisms of Nanoradiosensitizers.Nanomaterials (Basel). 2020 Mar 11;10(3):504. doi: 10.3390/nano10030504. Nanomaterials (Basel). 2020. PMID: 32168899 Free PMC article. Review.
-
Practical considerations for prostate hypofractionation in the developing world.Nat Rev Urol. 2021 Nov;18(11):669-685. doi: 10.1038/s41585-021-00498-6. Epub 2021 Aug 13. Nat Rev Urol. 2021. PMID: 34389825 Free PMC article. Review.
-
Robust Optimization for Prostate Radiation Therapy: Assessment of Delivered Dose by Incorporating Intrafraction Prostate Position Deviations.Adv Radiat Oncol. 2024 Feb 6;9(5):101455. doi: 10.1016/j.adro.2024.101455. eCollection 2024 May. Adv Radiat Oncol. 2024. PMID: 38596454 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources